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Despite major advances in under-
standing the genetics and epigenetics 
of acute myelogenous leukemia, there 
is still a great need to develop more 
specific and effective therapies. High 
throughput approaches involving 
either genetic approaches or small 
molecule inhibitor screens are begin-
ning to identify promising new thera-
peutic targets.  
One approach to develop new acute 
myelogenous leukemia (AML) thera-
pies has been to design mechanism-
based inhibitors. This has led to a num-
ber of new therapeutic agents entering 
clinical trials, including inhibitors of the 
DOT1L methyltransferase, BRD4 and 
IDH1/IDH2 [1]. This approach requires 
knowledge of the driver oncogenic mu-
tation and is limited to specific genetic 
subtypes of AML. A further challenge 
is that other cooperating oncogenes may 
confer chemotherapy resistance. 
An alternative approach is to screen 
for agents that overcome the block to 
myeloid differentiation seen in AML. 
The most notable success was the dis-
covery that trans retinoic acid (ATRA) 
induces differentiation of promyelocytic 
cell lines. This has led to the successful 
use of ATRA for patients with APL [2]. 
But how can similar agents to overcome 
differentiation block for the other 90% 
of AML cases be identified?
Sykes et al. [3] recently reported 
a powerful approach that should be 
broadly applicable to discovering new 
differentiation inducers in a wide range 
of AML cases. The authors noted that 
the homeobox-containing transcription 
factor HOXA9 is overexpressed in more 
than 50% of AML cases, including 
leukemias with MLL rearrangements, 
NUP98 translocations, NPM1 muta-
tions and CDX2/CDX4 overexpres-
sion. Furthermore, this deregulation 
is important for leukemogenesis [4]. 
The authors generated an inducible 
model of myeloid differentiation arrest 
by expressing an estrogen receptor-
HoxA9 (ER-Hoxa9) fusion protein in 
murine bone marrow cells. Addition 
of β-estradiol (E2) to ER-Hoxa9-ex-
pressing cells induces the translocation 
of ER-HoxA9 into the nucleus thereby 
blocking myeloid differentiation. These 
immortalized cells were arrested at the 
granulocyte-macrophage progenitor 
(GMP) stage, but undergo synchronous 
and terminal neutrophil differentiation 
upon E2 withdrawal. To facilitate the 
screening of small molecules stimulat-
ing myeloid differentiation, Sykes et al. 
generated a Lys-GFP-ER-HOXA9 cell 
line with the inducible HOXA9 using 
knockin mice, in which GFP is inserted 
into the lysozyme locus. Lysozyme is 
only expressed in mature granulocytes, 
so that GFP expression serves as a re-
porter for screening compounds that in-
duce differentiation (Figure 1). A library 
of 330 000 molecules was screened and 
of these, 12 induced myeloid differen-
tiation. The activity of these was further 
tested in other AML lines and two with 
distinct chemical scaffolds (C03 and 
C07) were selected for optimization 
because of their activity in both murine 
and human AML cells. 
The next challenge was to identify 
the protein target of the small molecules 
responsible for differentiating activity. 
The authors took the approach of grow-
ing the mouse and human cell lines for 
a long period in either C03 or C07 and 
analyzing the gene profiles of the drug-
resistant cells by RNA-Seq. The resis-
tant cells showed remarkably similar 
expression profiles, with up regulation 
of only eight shared genes that turned 
out to be located within a 100 Kb region 
of the long arm of human chromosome 
16 or murine chromosome 8. One of 
these genes encoded dihydroorotate 
dehydrogenase (DHODH), a critical 
enzyme in uridine synthesis that cata-
lyzes the conversion of dihydroorotate 
to orotate (Figure 1). Intriguingly, in 
addition to C03 and C07, all but one of 
the other 12 compounds identified in 
the small molecule screening were also 
found to be DHODH inhibitors.
These results strongly suggest that 
DHODH, and its downstream metabolic 
product uridine, regulate myeloid dif-
ferentiation. This possibility is further 
supported by the finding that uridine can 
rescue the blockage of cell differentia-
tion induced by DHODH inhibitors and 
that inhibiting orotidine 5′-phosphate 
decarboxylase, another essential en-
zyme regulating pyrimidine synthesis, 
causes a similar block in myeloid 
differentiation as that induced by the 
DHODH inhibitors. 
The authors developed a lead com-
pound ML390, derived from CO7, but 
it was found to be poorly bioavailable. 
Instead, for in vivo experiments, the 
authors chose a potent and selective 
inhibitor of DHODH, brequinar sodium 
(BRQ), which had been tested clini-
cally for other tumors, but not leukemia. 
Encouragingly, BRQ treatment signifi-
cantly induced myeloid differentiation, 
delayed the disease development and re-
duced the burden of leukemia-initiating 
cells in the various AML mouse models, 
including human cell line xenografts, 
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teins regulating differentiation. There 
is no shortage of candidates involved. 
Proteins known to be regulated by 
GlcNAcylation include RNA poly-
merase II, transcription factors such 
as c-MYC, and epigenetic regulators 
such as the Polycomb protein RING1B 
[6]. Aside from further delineating this 
mechanism, it will be important to 
test how broadly DHODH inhibition 
is effective given the heterogeneity of 
human leukemias and also what drugs 
will be most successful in combination 
with DHODH inhibition for complete 
eradication of leukemia.   
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Figure 1 Identification of DHODH as a target for differentiation therapy. Myeloid 
cells were conditionally immortalized by expression of estrogen receptor-HoxA9 
(ER-HOXA9) fusion protein in bone marrow cells in which GFP is inserted into 
the lysozyme locus. Removal of β-estradiol (E2) causes ER-HOXA9 to remain 
in the cytoplasm resulting in myeloid differentiation and expression of GFP and 
granulocyte markers such as CD11b. Screening 330 000 compounds led to the 
identification of small molecules promoting myeloid differentiation. Ultimately the 
target of the inhibitors was identified as DHODH, a key regulator of pyrimidine 
biosynthesis. 
AML therapy. Notably, using a genetic 
approach, a CRISPR “dropout” screen, 
Tzelepis et al. [5] found that a variety 
of AML cell lines are selectively vulner-
able to DHODH depletion.  
While the precise targets affected 
by DHODH inhibition remain to be 
identified, since DHODH is required for 
UDP-GlcNAc formation and DHODH 
inhibition reduced protein O-linked 
N-glycosylation in the AML cells, 
the inhibitor effects may be mediated 
through reduced glycosylation of pro-
patient-derived xenografts, and synge-
neic mouse models caused by a variety 
of genetic alterations. 
The experimental approach of Sykes 
et al. is a powerful example of how high 
throughput strategies can be employed 
to identify new targets in AML and other 
malignancies. In particular the results 
show considerable promise for DHODH 
inhibitors, which have previously been 
used for treatment of other cancers, 
such as melanoma as well as rheuma-
toid arthritis and multiple sclerosis, for 
